GLP-1 medications without insurance: every cost pathway in 2026

What 'without insurance' actually means for GLP-1s

Most people without GLP-1 insurance coverage don't face a single price — they face a choice between several distinct pathways, each with a different cost structure, a different product (brand vs. compounded), and different legal status. The retail pharmacy price is the highest, but almost no one who seeks out self-pay options actually pays it. Understanding the landscape takes five minutes and can save thousands of dollars a year.

Compounded semaglutide: the lowest-cost pathway

Compounded semaglutide from a 503A pharmacy dispensed through a telehealth provider is consistently the cheapest GLP-1 option for cash-pay patients. The price ranges from roughly $150 to $299 a month depending on provider, dose, and how the membership or visit fees are structured. The medication is pharmacy-mixed rather than FDA-approved as a finished product — a distinction that matters for some women and not for others.

The legal landscape for compounded semaglutide has narrowed since the FDA declared the semaglutide shortage resolved. Providers operating today do so under a 503A individual-patient pathway, which requires a documented clinical reason the approved medication won't work for that specific patient. Several major telehealth providers continue to operate this way. Confirm with any provider how they currently document and source compounded semaglutide before enrolling.

Fridays — starting around $150/mo

Fridays quotes compounded semaglutide starting at approximately $150 a month for the starter dose, with prices rising through the titration schedule. The all-in quote includes medication, clinical consult, and shipping. Ask for the full dose ladder at current prices before enrolling — the starter price may not reflect your ongoing cost at maintenance dose.

Mochi Health — flat $99 medication fee plus membership

Mochi charges $99 a month for semaglutide medication at any dose — a dose-flat structure that can be valuable during titration when other programs raise the fee with each step up. There's a separate $79 a month membership fee, bringing the true all-in total to approximately $178. The obesity-medicine physician model is a clinical differentiator for women who want active medical oversight rather than a prescription-and-ship service.

Henry Meds — bundled $197–$297/mo

Henry Meds bundles visits, medication, supplies, and shipping into a single all-in monthly price. Compounded semaglutide runs approximately $197 a month at starter doses, rising to $297 at higher doses. They also offer oral tirzepatide as an option for women who prefer to avoid injections. No long-term contract; cancel anytime.

Brand-name self-pay programs: lower than you think

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have introduced self-pay programs that substantially undercut retail pharmacy prices. These are FDA-approved products from the manufacturers — not compounded — and the self-pay programs have brought the price within range of compounded options for some doses.

NovoCare Wegovy self-pay

Novo Nordisk's NovoCare program offers Wegovy to self-pay patients at $199 a month introductory, rising to $349 a month ongoing. This is FDA-approved, brand-name semaglutide injection at a price that competes with some compounded programs. It requires a prescription, is ordered through the NovoCare pharmacy, and is not available through retail pharmacies at this price.

LillyDirect Zepbound vials

Eli Lilly sells Zepbound (tirzepatide) single-dose vials directly to self-pay patients at $299 a month for 2.5mg, $399 for 5mg, and $449 for 7.5mg through 15mg. These are brand-name, FDA-approved medications. The 45-day refill window is the most important fine print — missing it triggers a jump to standard pharmacy pricing. Set a calendar reminder.

Why GLP-1s matter especially for women in perimenopause

GLP-1 medications are particularly relevant during the perimenopausal transition, not just for general weight management. As estrogen declines, fat redistributes toward the abdomen, insulin sensitivity decreases, and the appetite-regulating hormones leptin and GLP-1 itself become less effective — which is why the same diet and exercise approach that worked at 38 often stops working at 46. GLP-1 receptor agonists directly address these hormonal metabolic disruptions, making them a well-matched tool for this specific life stage.

Some menopause-specialist clinicians now combine GLP-1 therapy with hormone replacement therapy, addressing both the hormonal root cause and the metabolic consequence simultaneously. Neither replaces the other — they work on different mechanisms.

Annual cost comparison: picking your pathway

• Fridays compounded semaglutide (starter ~$150/mo): ~$1,800/year — but titration means ongoing doses cost more.
• Mochi Health all-in (~$178/mo): ~$2,136/year — dose-flat advantage matters most at higher doses.
• Henry Meds (~$197–$297/mo): ~$2,364–$3,564/year depending on dose progression.
• NovoCare Wegovy self-pay (~$349/mo ongoing): ~$4,188/year after introductory period.
• LillyDirect Zepbound, starter dose ($299/mo): ~$3,588/year.
• LillyDirect Zepbound, maintenance dose ($449/mo): ~$5,388/year.
• Retail pharmacy with GoodRx (~$300–$500/mo): ~$3,600–$6,000/year.
• Retail, no discount (~$1,086–$1,350/mo): ~$13,000–$16,200/year.